Saturday, January 24, 2026

 

U.S. Rural hospital bypass by patients with commercial health insurance




JAMA Network Open


About The Study: 


Rural hospital bypass (when rural residents receive care at hospitals other than their nearest hospital) rates among commercially insured patients were substantial between 2012 and 2021, generating large payments to receiving hospitals. Relative to Medicare bypass rates, commercial bypass rates were high in this sample. The findings of this study support concerns that commercial bypass contributes to financial distress at rural hospitals.



Corresponding Author: To contact the corresponding author, Caitlin E. Carroll, PhD, email carrollc@umn.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2025.55017)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article 

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.55017?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=012226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

The face scars less than the body — a Stanford Medicine study unravels why




Stanford Medicine





Tweaking a pattern of wound healing established millions of years ago may enable scar-free injury repair after surgery or trauma, Stanford Medicine researchers have found. If results from their study, which was conducted in mice, translate to humans, it may be possible to avoid or even treat the formation of scars anywhere on or within the body.

Scarring is more than a cosmetic problem. Scars can interfere with normal tissue function and cause chronic pain, disease and even death. It’s estimated that about 45% of deaths in the United States are due to some type of scarring (also known as fibrosis) — usually of vital organs like the lungs, liver or heart.

Scars on the skin’s surface, while rarely fatal, are stiffer and weaker than normal skin and they lack sweat glands or hair follicles, making it difficult to compensate for temperature changes.

Surgeons have known for decades that facial wounds heal with less scarring than injuries on other parts of the body. This phenomenon makes evolutionary sense: Rapid healing of body wounds prevents death from blood loss, infection or impaired mobility, but healing of the face requires that the skin maintain its ability to function well.

“The face is the prime real estate of the body,” said professor of surgery Michael Longaker, MD. “We need to see and hear and breathe and eat. In contrast, injuries on the body must heal quickly. The resulting scar may not look or function like normal tissue, but you will likely still survive to procreate.”

Exactly how this discrepancy happens has remained a mystery, although there were some clues.

“The face and scalp are developmentally unique,” said professor of surgery Derrick Wan, MD. “Tissue from the neck up is derived from a type of cell in the early embryo called a neural crest cell. In this study we identified specific healing pathways in scar-forming cells called fibroblasts that originate from the neural crest and found that they drive a more regenerative type of healing.”

Activating this pathway in even a subset of fibroblasts around small wounds on the abdomen or backs of mice caused them to heal with much less scarring — similar to untreated facial or scalp wounds.

Longaker, the Deane P. and Louise Mitchell Professor in the School of Medicine, and Wan, the Johnson & Johnson Distinguished Professor in Surgery II, are the senior authors of the study, which was published Jan. 22 in Cell. Plastic surgery resident Michelle Griffin, MD, PhD, and clinical and postdoctoral scholar Dayan Li, MD, PhD, are the lead authors of the research.

“Many of the authors on this paper are fellow physician scientists,” said Li, who is board certified in dermatology. “This project was inspired by what we’ve observed in our patients — facial wounds in general heal with less scarring. We wanted to understand, mechanistically, why this is.”

Proteins determine scarring

Li and his colleagues used laboratory mice to investigate differences in wound healing at various sites on the animals’ bodies. They anesthetized the mice before creating small skin wounds on the face, scalp, back and abdomen. The wounds were stabilized by suturing small plastic rings around them to prevent differences in mechanical forces as the animals moved. Mice were given pain relief during the healing process.

After 14 days, the wounds on the face and scalp expressed lower levels of proteins known to be involved in scar formation as compared with those on the abdomen or back of the animals. The sizes of the scars were also smaller.

The researchers then transplanted skin from the face, scalp, back and abdomen of mice onto the backs of control mice. After the transplants had engrafted, they repeated the experiment on the transplanted skin. As before, wounds in the skin transplanted from the faces of the donor mice expressed lower levels of scarring-associated proteins.

Additionally, Li and his colleagues isolated fibroblasts from skin samples from the four body sites in the donor mice and injected them into the backs of control mice. They observed reduced levels of scarring-associated proteins on the recipient animals’ backs injected with fibroblasts from the donor animals’ faces as compared with fibroblasts from the scalp, back or abdomen.

“We found you don’t need to change or manipulate all fibroblasts within the tissue to have a positive outcome,” Li said. “When we injected fibroblasts that we had genetically altered to more closely resemble facial fibroblasts, we saw that the back incisions healed very much like facial incisions, with reduced scarring, even when the transplanted fibroblasts made up only 10% to 15% of the total number of surrounding fibroblasts. Changing just a few cells can trigger a cascade of events that can cause big changes in healing.”

A less-fibrotic wound healing

Digging deeper, the researchers identified changes in gene expression between facial fibroblasts and those from other parts of the body and followed these clues to identify a signaling pathway involving a protein called ROBO2 that maintains facial fibroblasts in a less-fibrotic state. They also saw something interesting in the genomes of fibroblasts making ROBO2.

“In general, the DNA of the ROBO2-positive cells is less transcriptionally active, or less available for binding by proteins required for gene expression,” Li said. “These fibroblasts more closely resemble their progenitors, the neural crest cells, and they might be more able to become the many cell types required for skin regeneration.”

In contrast, the DNA in fibroblasts from other sites of the body allows free access to genes like collagen that are involved in the creation of scar tissue.

“It seems that, in order to scar, the cells must be able to express these pro-fibrotic genes,” Longaker said. “And this is the default pathway for much of the body.”

ROBO2 doesn’t act alone. It triggers a signaling pathway that results in the inhibition of another protein called EP300 that facilitates gene expression. EP300 plays an important role in some cancers, and clinical trials of a small drug molecule that can inhibit its activity are underway. Li and his colleagues found that using this pre-existing small molecule to block EP300 activity in fibroblasts prone to scarring caused back wounds to heal like facial wounds.

“Now that we understand this pathway and the implications of the differences among fibroblasts that arise from different types of stem cells, we may be able to improve wound healing after surgeries or trauma,” Wan said.

The findings are likely to extend to internal scarring as well, Longaker said. “There’s not a million ways to form a scar,” he said. “This and previous other findings in my lab suggest there are common mechanisms and culprits regardless of the tissue type, and they strongly suggest there is a unifying way to treat or prevent scarring.”

Researchers from the University of Arizona contributed to the work.

The study was funded by the National Institutes of Health (grants R01-GM136659, U24DE029463, R01-DE032677, R01-AR081343, RM1-HG007735 and 5T32AR007422-43), The Hagey Laboratory for Pediatric Regenerative Medicine, the Wu Tsai Human Performance Alliance, the Scleroderma Research Foundation, the A.P. Giannini Foundation and the Howard Hughes Medical Institute.

Longaker is an inventor on a patent application that covers a machine-learning algorithm for analysis of connective tissue networks in scarring and chronic fibroses.

Longaker is a member of Stanford’s Bio-X, the Stanford Cardiovascular Institute, the Wu Tsai Human Performance Alliance, the Institute for Stem Cell Biology and Regenerative Medicine, the Maternal and Child Health Research Institute, and the Stanford Cancer Institute.

# # #

 

About Stanford Medicine

Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.

 

XXI CENTURY ALCHEMY

'Trojan horse' may deliver toxic dose of copper to bacterial colonies, including drug-resistant MRSA infections




University of Arizona




A research team at the University of Arizona College of Medicine – Tucson is developing a drug that works in combination with copper to kill bacteria, including those that cause MRSA, a type of staph infection that is resistant to usual treatments. They published their results last month in mSphere.

MRSA is caused by methicillin-resistant Staphylococcus aureus, which is classified as a serious threat by the Centers for Disease Control and Prevention and a high-priority pathogen by the World Health Organization.

"It likes to live on our skin – about 30% of people are colonized with it. It becomes a problem when it gets in a wound, where it can wreak havoc," said Michael D. L. Johnson, an associate professor of immunobiology and senior author of the paper.

While MRSA can be treated with other antibiotics, bacteria's ability to evolve drug resistance means finding novel treatments is crucial.

"History has shown us that bacteria have an exquisite ability to adapt to their surroundings," Johnson said. "The more tools we have in our toolkit, the better prepared we will be to fight the next threat."

MRSA can be spread by skin-to-skin contact and appear as a painful boil. It can also occur in a hospital setting, where it might colonize a surgical wound or be introduced to the body through tubing, such as a catheter, or an implant, such as an artificial joint.

"People who are diabetic are very susceptible to staph infections, specifically in wounds they may develop," Johnson said. "It also binds to plastic really well. Can you guess where there's a lot of plastic? In a hospital. We've become quite reliant on plastic, which creates a niche for that microbe."

The team also looked at a cousin of MSRA, Staphylococcus epidermidis, which is usually harmless but can cause infections in hospitals due to its affinity for plastic. Both MSRA and S. epidermidis adhere to plastic by producing a "glue" called biofilm.

"That stuff you feel on your teeth when you wake up in the morning – that's biofilm," Johnson said. "Bacteria make biofilm to hold on to host cells or surfaces, and that biofilm is a protective shield from the bacteria's environment – such as antibiotics or antimicrobial peptides our bodies make."

Supported by funding from Tech Launch Arizona, the Johnson Lab designed the platform for a molecule called BMDC, short for N-benzyl-N-methyldithiocarbamate, to work with copper, based on a similar molecule they studied previously. TLA provided the funds through its Asset Development Program, which provides support to move potentially impactful innovations closer to readiness for commercialization and real-world impact.

"This one actually worked better than our original compound, DMDC, which killed different Streptococcusspecies – but not staph," Johnson said.

He says BMDC works by disguising itself as iron, a nutrient that hungry bacteria scavenge from their surroundings. But instead of iron, the compound contains a toxic dose of copper.

"Our compound mimics specialized molecules that carry iron. The staph bacteria are like, 'Oh, sweet, iron! This is my lucky day!' They unlock the compound, and, oops, it's copper," he explained. "Our compound is a Trojan horse, intoxicating bacteria with copper, killing them within the biofilm. The bacteria don't learn from their mistakes, and they do it over and over again."

Working with TLA, Johnson has filed a patent application on the technology, and they are searching for a company to license the product to develop it further. Their plan is to take it to clinical trials in humans, which they hope will lead to FDA approval to treat MRSA and other infections.

In the meantime, the Johnson Lab is preparing to launch a collaboration with the Department of Surgery's Division Chief of Pediatric Surgery Kenneth W. Liechty, to conduct additional laboratory experiments to see if their compound helps with wound infections and healing.

"How amazing would it be if someday, we could put some of our stuff on an open wound with a bad infection, and the infection got better?" said Johnson, who is also a member of the BIO5 Institute. "We're very interested in the translation of our discoveries to the clinic, and you don't do that unless you're partnered with amazing people here at U of A to do those experiments."

Johnson says the possibility that his work in the lab could someday benefit humanity is profoundly inspiring.

"Those are the things basic science and translational researchers dream about," he said. "It makes the science more exciting when you can see the application at the end of the road."

This research is supported in part by the National Institute of General Medical Sciences, a division of the National Institutes of Health, under award No. 2R35128653.

ABOLISH PBM MIDDLE MEN 

PBM profits obscured by mergers and accounting practices, USC Schaeffer white paper shows



Requiring more financial transparency from PBMs would help policymakers understand how money flows through the large healthcare companies that now own them




University of Southern California




Pharmacy benefit managers (PBMs) under the microscope for their role in high drug prices have often cited their reportedly slim profit margins as evidence that they do not drive up costs. The three leading PBMs, which control about 80% of the prescription drug market, have historically reported profit margins of 4% to 7%, among the lowest in the healthcare industry.

A new white paper from the USC Schaeffer Center for Health Policy & Economics demonstrates that these slim margins are dramatically influenced by the accounting practices PBMs elect to employ. The paper also shows how efforts to assess PBM profits have become more challenging after these companies merged with healthcare conglomerates that own other players in the pharmaceutical supply chain.

States in recent years have advanced or considered numerous measures seeking to increase PBM transparency, and Congress is currently pursuing legislation to reform PBM practices. The Federal Trade Commission, meanwhile, continues to scrutinize PBMs after accusing leading firms of inflating drug costs through strategies like rebates, markups and preferential treatment of affiliated pharmacies.

“Accounting practices make it difficult to judge the health and efficiency of the PBM market, particularly as dominant firms have become part of larger, more complex companies,” said lead author Karen Mulligan, a research scientist at the Schaeffer Center. “Greater financial disclosure requirements for PBMs are needed to develop a better picture of how PBMs make money and the extent to which these practices may raise costs for consumers.”

How accounting choices drive margins

PBMs sit at the center of the pharmaceutical supply chain, acting as intermediaries that pay pharmacies and negotiate rebates with drug manufacturers on behalf of insurers. PBMs retain transaction fees and a portion of manufacturer rebates while passing along payments between manufacturers, insurers and pharmacies.

Historically, PBMs have included these “pass-through payments” in financial reporting. This may also include the share of rebates sent directly to the insurer. While allowed under professional accounting guidelines, this practice may add hundreds of billions of dollars to PBMs’ reported revenue or expenses without affecting their actual earnings. This obscures key determinants of PBMs’ profitability, including the role of rebates, fees and other payments.

Using a simplified example with typical transaction fees and rebates, the white paper illustrates how accounting choices can produce vastly different profit margins for a hypothetical drug listed at $360. If pass-through payments were reported as revenues or expenses, the PBM’s margin would be 10% – or slightly higher at 13% if manufacturer rebates passed to the insurer were not reported. However, the margin jumps to 87% if pass-through payments were not reported at all. (See Figure 5 in the white paper.)

Vertical integration in the healthcare industry has further blurred PBMs’ financial picture. In the past decade, the three dominant PBMs have become part of diverse healthcare corporations that also own insurers, specialty pharmacies and group purchasing organizations (GOPs) that negotiate discounts.

Under this structure, payments between the PBM, insurer and the specialty pharmacy become internal transfers invisible to the public. Using the same hypothetical $360 drug as the previous example, the white paper shows how the publicly reported profit margin can be half of what’s recorded internally, as dollars are shifted to other units within the PBM’s parent company. (See Figure 6.)

Transparency reforms should illuminate revenue streams

The researchers suggest that policymakers consider requiring PBMs to exclude pass-through payments from financial reporting, as regulators have done for intermediaries in other industries.

Policymakers should also consider reforming financial reporting requirements so that healthcare conglomerates provide separate reporting for each distinct business unit, rather than allowing PBM operations to be combined with other units like specialty pharmacy. Further, requiring disclosure of internal transfers and pass-through payments in these companies would provide clarity about what’s driving profits.

“True transparency requires greater visibility into profit flows hidden inside increasingly complex corporate structures,” said co-author Darius Lakdawalla, chief scientific officer at the Schaeffer Center and the Quintiles Chair of Pharmaceutical Development and Regulatory Innovation at the USC Mann School. “Building a more efficient and sustainable pharmaceutical supply chain starts with a better understanding of where dollars are flowing.”